Eli Lilly Says Retatrutide Shows Cardiovascular, Diabetic Benefits
Eli Lilly reports positive Phase 3 data for retatrutide, showing major weight loss in adults. US regulatory submission is planned for 2027.
Eli Lilly tested a new medicine that helped people lose weight and stay healthier, and they plan to ask the government to approve it in a few years. This is good progress, but we have to wait a long time to see if it actually becomes available to patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.